

Board of Members of the Global AMR R&D Hub

Recommendations to the G20 following the first analysis report of Dynamic Dashboard data

- November 2020 -

Introduction


The Global AMR R&D Hub was launched in May 2018, following a call from G20 Leaders, to address challenges and improve coordination and collaboration in global AMR R&D using a One Health approach. The Dynamic Dashboard, established throughout the year 2020, is one of the first major achievements of the Hub. It aims to support evidence-based decision making and priority setting and to help maximize the impact and efficiency of resources and efforts invested into AMR R&D.

Content and scope of the Dynamic Dashboard

- The Dynamic Dashboard continuously collects and presents information on AMR R&D investments across the One Health spectrum. Currently, it presents information on investments since January 2017 from public and not-for profit private funders into AMR R&D related to human bacterial infections and animal pathogens. As at September 2020, a total of 7496 projects from 141 funders with a total investment of 5.6 billion USD were captured.
- Geographical coverage across all continents has been achieved, representing 34 countries and the European Union and continues to be improved. The Dynamic Dashboard will be expanded to the plant and environment One Health sectors in early 2021.
- The Dynamic Dashboard also presents the pipeline of antibacterials in clinical development and incentives for antibacterials R&D.
- This is the first consolidation of national AMR-related R&D funding and a start to providing a comprehensive global picture. The first analysis report provides a baseline, essentially representing two full years of data (2017 and 2018). Over time, more data will enable meaningful trend analysis.

Analyses in progress

- Linkages between funders will be the first priority for detailed analyses. In parallel, further analysis of push and pull incentives will be prioritised – and how the Dashboard data on funding can support this.
- The outcomes and resulting analysis will help to identify opportunities and gaps in AMR R&D and inform about progress in the AMR R&D field.
- The value of the consolidated data lies in these types of analyses to provide the evidence-base for policy makers.



Key messages that can already be drawn from the Dynamic Dashboard

- Data averaged at the global level shows that most funding is directed towards basic research, followed by funding for R&D on therapeutics and support for operational and implementation research.
- The distribution of investments by public and philanthropic funders into AMR R&D across pathogens overall aligns well with the priority ranking of the bacteria on the priority lists developed by the WHO and the US CDC.
- Translation of this investment into new antibiotics in clinical development is not yet functioning optimally. The pipeline remains fragile, with low numbers and relatively weak innovativeness and with only about two fifths of the compounds in development or recently approved addressing some of the most critical pathogens.
- Building on the significant investment in early stage product development by public and philanthropic funders, **more support for late stage clinical development is considered necessary to maintain the momentum and support the required infrastructure for bringing new antibiotics to patients.**
- Pull support, to overcome some of the economic challenges in therapeutic markets following approval remains *ad hoc*, small-scale and initiated by just a few countries globally. **More countries need to come forward with pull-incentives at an adequate scale. Initiatives across countries need to be aligned so as to create a strong signal to investors.**
- A significant amount of global AMR R&D investment occurs at the international level, through joint funding of initiatives, joint calls or through the investments of the European Union. In line with the recommendations of the Interagency Coordination Group (IACG), **more should be done to increase cooperation and enforce concerted action on a global One Health R&D response to the threat of AMR. Supporting this effort is one of the major goals of the Global AMR R&D Hub.**
- Industry should be encouraged to contribute their data to the Dynamic Dashboard, as without it the picture will remain incomplete.

These recommendations are based on the report “The state of public and philanthropic investments in AMR R&D - The 2020 annual report of the Global AMR R&D Hub’s Dynamic Dashboard”.

The report can be found on the Global AMR R&D Hub website at:

<https://globalamrhub.org/wp-content/uploads/2020/11/GlobalAMRHubReportDD.Nov2020.pdf>